AMERICAN ACADEMY OF NEUROLOGY

This year, the 74^th annual meeting is a hybrid event. It was held in person in Seattle and will be available as a distinct virtual experience later in April.

The presentations downloaded using this platform are intended as an educational resource for legitimate scientific exchange and not for promotional use.

AMERICAN ACADEMY OF NEUROLOGY

Due to the COVID-19 pandemic, the 73^rd AAN annual meeting was held in a fully virtual format from April 17-22.

The presentations downloaded using this platform are intended as an educational resource for legitimate scientific exchange and not for promotional use.

AMERICAN ACADEMY OF NEUROLOGY

Due to the COVID-19 pandemic, the AAN cancelled the 72^nd annual meeting. This site enables you to access the presentations that were supposed to be presented if the AAN had happened.

The presentations downloaded using this platform are intended as an educational resource for legitimate scientific exchange and not for promotional use.

Efficacy and Safety of Erenumab 70 mg in Adult Patients with Chronic Migraine: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled DRAGON Study

Wang SJ, et al; Oral presentation S31. 005

Abstract

Long-term Safety and Tolerability of Erenumab in Episodic Migraine: A Pooled Analysis From Two Clinical Trials and Their Extension Phases

Ashina M, et al; ePoster P3.2-005

Abstract

A Real-world, Observational Study of Erenumab for Migraine Prevention in Canadian Patients with Prior Prophylactic Treatment Failure

Becker W, et al; ePoster P10.2-002

Abstract

Erenumab Versus Topiramate for the Prevention of Migraine: Results of a Post-hoc Efficacy Analysis

Ehrlich M, et al; ePoster P16.2-004

Abstract

Effect of Erenumab on Patient-reported Outcomes in Patients with Episodic Migraine From Asia, the Middle East and Latin America: The EMPOwER Study

Wang SJ, et al; ePoster P16.2-006

Abstract

Real-world Healthcare Costs and Resource Utilization Among Patients Treated with Erenumab in the United States: A Retrospective Claims Database Study

Tepper SJ, et al; ePoster P16.7-003

Abstract

Three-year Efficacy and Safety of Erenumab in Participants with Episodic Migraine and 2–4 Prior Preventive Treatment Failures: Results From the LIBERTY Study

Reuter U, et al; Virtual poster

Abstract

Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study

Ashina M, et al; ePoster: P10.001

Abstract

Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study

Tepper S, et al; ePoster: P10.032

Abstract

Risk of hypertension in erenumab-treated patients with migraine in clinical trials and in the post marketing setting

Dodick D, et al; ePoster: P10.044

Abstract

Design and population characteristics of patients treated with monoclonal antibody erenumab for assessment of long-term safety and tolerability and frequency of drug holidays in Germany (APOLLON)

Ortler S, et al; ePoster: P10.047

Abstract

Long-term efficacy of erenumab in chronic migraine (CM) patients with or without acute medication overuse (AMO)

S. Tepper, R. B. Lipton, S. Silberstein, D. Kudrow, M. Ashina, U. Reuter, D. Dodick, F. Zhang, S. Cheng, D. D. Mikol

Poster number: P2.6-002

Published Abstract

First-hand impressions of the monoclonal antibody erenumab from treated patients in Germany

C. Gaul, H. Israel-Willner, M. Koch, K. Schuh

Poster number: P3.6-001

Published Abstract

First real-world evidence data for the monoclonal antibody erenumab from specialized migraine centers in Germany

A. Straube, P. Stude, K. Schuh, M. Koch

Poster number: P3.6-005

Published Abstract

Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: 4+ year results of a 5-year, open-label treatment period

M. Ashina, P. J. Goadsby, U.Reuter, S. Silberstein,D.W.Dodick, D. E. Chou, J. Klatt, F. Xue, F. Zhang, S. Cheng, D. D. Mikol

Oral presentation: S8.001

Published Abstract

Benefit of migraine prevention with erenumab in patients receiving background standard-of-care acute treatment

A. Starling, S. Tepper, C. Bernstein, J. Ailani, F. Zhang, G. Paiva da Silva Lima, D. E. Chou

Oral presentation: S8.006

Published Abstract

Safety and tolerability of erenumab in older migraine patients: A subgroup analysis of randomised trials

C. Lampl, J. Snellman, S. Ritter, J. Klatt

Poster number: P7.6-004

Published Abstract

Changes in acute migraine-specific medications after initiating erenumab: Results from a real-world retrospective cohort study in the United States

SD. M. Hines, S. Shah, J. K. Multani,R. L. Wade, D. C. Buse, M. E. Bensink

Poster number: P11.6-001

Published Abstract

Impact of an employer-provided migraine coaching program on burden and patient engagement: Results from interim analysis

L. Schaetz, T. Rimner, P. Pathak, J. Fang, D. Chandrasekhar, J. Mueller

Oral presentation: S47.004

Published Abstract

Migraine polygenic risk score is associated with severity of migraine: Analysis of genotypic data from four placebo-controlled trials of erenumab

D.D. Mikol, H. Picard, J. Klatt, A. Wang, C. Peng, K. Stefansson

Oral presentation: S47.006

Published Abstract

Economic burden increased with number of treatment failure in migraine patients: A retrospective claims database analysis in the united states

L. Newman, J. Huels, P. Vo, L. Zhou, C. Lopez Lopez, A. Cheadle, M. Olson, J. Fang

Oral presentation: S47.009

Published Abstract

Cardiovascular safety of erenumab in patients with migraine and aura

M. Ashina, P. J Goadsby, D.W.Dodick, S. J Tepper, F. Xue, F. Zhang, J. Olearczyk, G. Paiva da Silva Lima

Oral presentation: S58.010

Published Abstract

AMERICAN ACADEMY OF NEUROLOGY

AMERICAN ACADEMY OF NEUROLOGY

AMERICAN ACADEMY OF NEUROLOGY

April 02-07 | Seattle, April 24-26 | Virtual

AAN 2022 Annual Meeting

April 17-22 | Virtual

AAN 2021 Virtual Annual Meeting

April 25-May 1 | Toronto, Canada

AAN 2021 Virtual Annual Meeting

Efficacy and Safety of Erenumab 70 mg in Adult Patients with Chronic Migraine: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled DRAGON Study

Long-term Safety and Tolerability of Erenumab in Episodic Migraine: A Pooled Analysis From Two Clinical Trials and Their Extension Phases

A Real-world, Observational Study of Erenumab for Migraine Prevention in Canadian Patients with Prior Prophylactic Treatment Failure

Erenumab Versus Topiramate for the Prevention of Migraine: Results of a Post-hoc Efficacy Analysis

Effect of Erenumab on Patient-reported Outcomes in Patients with Episodic Migraine From Asia, the Middle East and Latin America: The EMPOwER Study

Real-world Healthcare Costs and Resource Utilization Among Patients Treated with Erenumab in the United States: A Retrospective Claims Database Study

Three-year Efficacy and Safety of Erenumab in Participants with Episodic Migraine and 2–4 Prior Preventive Treatment Failures: Results From the LIBERTY Study

Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study

Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study

Risk of hypertension in erenumab-treated patients with migraine in clinical trials and in the post marketing setting

Design and population characteristics of patients treated with monoclonal antibody erenumab for assessment of long-term safety and tolerability and frequency of drug holidays in Germany (APOLLON)

Long-term efficacy of erenumab in chronic migraine (CM) patients with or without acute medication overuse (AMO)

First-hand impressions of the monoclonal antibody erenumab from treated patients in Germany

First real-world evidence data for the monoclonal antibody erenumab from specialized migraine centers in Germany

Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: 4+ year results of a 5-year, open-label treatment period

Benefit of migraine prevention with erenumab in patients receiving background standard-of-care acute treatment

Safety and tolerability of erenumab in older migraine patients: A subgroup analysis of randomised trials

Changes in acute migraine-specific medications after initiating erenumab: Results from a real-world retrospective cohort study in the United States

Impact of an employer-provided migraine coaching program on burden and patient engagement: Results from interim analysis

Migraine polygenic risk score is associated with severity of migraine: Analysis of genotypic data from four placebo-controlled trials of erenumab

Economic burden increased with number of treatment failure in migraine patients: A retrospective claims database analysis in the united states

Cardiovascular safety of erenumab in patients with migraine and aura

Click here for all published abstracts

For more details please visit:

Click here for all published abstracts

Click here for all published abstracts